Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gene2Us Corp. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is distributed across 1 distinct examiner and 1 distinct art unit, showing a concentrated effort in a specific technical domain. The current state of the portfolio involves a singular interaction with the patent office, which simplifies the management of deadlines and examiner communications. This focused approach suggests that the company is navigating a specific regulatory path for its current intellectual property.
The busiest examiner for the company is OLSON, ANDREA STEFFEL, who is currently overseeing 1 pending office action. This 1 pending office action accounts for the total pending volume for Gene2Us Corp. at this time. With 1 distinct art unit involved, the prosecution remains within a specific technical framework. Practitioners can focus their strategy on the specific preferences and history of OLSON, ANDREA STEFFEL to navigate the pending action effectively. The alignment of the portfolio within the Biotechnology & Pharmaceuticals area allows for a direct focus on the requirements of this assigned official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.5% | -11.9% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923177 | BUFFER COMPOSITION FOR NUCLEIC ACID ISOLATION FOR COLUMN-BASED ONE-TUBE PCR, AND USE THEREOF | OLSON, ANDREA STEFFEL | 1693 | §103 | Final Rejection | — | Pending | Nov 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGene2Us Corp. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Andrea Steffel Olson has the most, with 1 of Gene2Us Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.